Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 2
1954 1
1965 1
1974 1
1979 1
1981 1
1983 4
1984 1
1987 2
1988 1
1989 1
1990 1
1991 2
1992 3
1993 2
1994 1
1995 4
1996 1
1997 4
1998 3
1999 2
2000 8
2001 3
2002 3
2003 3
2004 8
2005 1
2006 1
2007 1
2008 1
2009 2
2010 5
2011 4
2012 2
2013 10
2014 5
2015 5
2016 4
2017 1
2018 3
2019 7
2020 13
2021 11
2022 13
Text availability
Article attribute
Article type
Publication date

Search Results

138 results
Results by year
Filters applied: . Clear all
Page 1
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Soumerai JD, et al. Among authors: barnes ja. Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0. Lancet Haematol. 2021. PMID: 34826411 Clinical Trial.
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Bannerji R, et al. Among authors: barnes ja. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1. Lancet Haematol. 2022. PMID: 35366963 Clinical Trial.
Introduction: Health, Well-Being, and Ability in Archaeology.
Camp SL, Barnes JA, Surface-Evans S. Camp SL, et al. Among authors: barnes ja. Int J Hist Archaeol. 2022 Jan 8:1-16. doi: 10.1007/s10761-021-00645-0. Online ahead of print. Int J Hist Archaeol. 2022. PMID: 35035208 Free PMC article.
Endoscopic Management of Early Esophageal Cancer.
Barnes JA, Willingham FF. Barnes JA, et al. J Clin Gastroenterol. 2015 Sep;49(8):638-46. doi: 10.1097/MCG.0000000000000353. J Clin Gastroenterol. 2015. PMID: 26125458 Review.
Hadamard-Transform Fluorescence Excitation-Emission-Matrix Spectroscopy.
Andrews NLP, Ferguson T, Rangaswamy AMM, Bernicky AR, Henning N, Dudelzak A, Reich O, Barnes JA, Loock HP. Andrews NLP, et al. Among authors: barnes ja. Anal Chem. 2017 Aug 15;89(16):8554-8564. doi: 10.1021/acs.analchem.7b02400. Epub 2017 Aug 4. Anal Chem. 2017. PMID: 28718629
Chemical sensing using fiber cavity ring-down spectroscopy.
Waechter H, Litman J, Cheung AH, Barnes JA, Loock HP. Waechter H, et al. Among authors: barnes ja. Sensors (Basel). 2010;10(3):1716-42. doi: 10.3390/s100301716. Epub 2010 Mar 2. Sensors (Basel). 2010. PMID: 22294895 Free PMC article. Review.
138 results